MicroPort Announced 12-Month Follow-Up Result of FOCUS
The 5th Oriental Congress of Cardiology (OCC 2011) was held at Shanghai International Convention Center from May 26 to May 29. During the congress, MicroPort organized a satellite meeting on the application of Firebird2 drug-eluting stents in the treatment of small vessel disease and tortuous lesions, and simultaneously announced the final result of its clinical-registered study FOCUS.
According to the 12-month follow-up of FOCUS, the success rate was high, with 99.81% lesion achievement ratio and 99.72% case achievement ratio. It was also shown that the 12-month cumulative cardiac death rate was 0.84%, the incidence of TVR, MACE and Late Thrombosis were 0.90%, 3.43% and 0.75%, respectively. The follow-up data further validated and proved the clinical safety and efficacy of Firebird2 drug-eluting stents.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.